Reaction
B-Cell Lymphoma Recurrent reporting signals
As of the last recalculation, B-Cell Lymphoma Recurrent appears in 535 FAERS reports alongside 27 co-occurring drug terms. The strongest observed disproportionality signal is BENDAMUSTINE HCL (PRR 201.9).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Bendamustine Hcl | 70 | 201.9 | 202.8 |
| Doxorubicin | 244 | 195.0 | 195.6 |
| Rituximab | 325 | 150.8 | 151.1 |
| Axicabtagene Ciloleucel | 27 | 112.0 | 112.4 |
| Obinutuzumab | 37 | 93.9 | 94.1 |
| Ifosfamide | 46 | 91.0 | 91.2 |
| Cyclophosphamide Injection, Solution | 230 | 87.9 | 88.0 |
| Cyclophosphamide | 230 | 87.9 | 88.0 |
| Cyclophosphamide For Injection | 230 | 87.9 | 88.0 |
| Doxorubicin Hydrochloride | 61 | 81.9 | 82.0 |
| Melphalan | 36 | 65.9 | 66.0 |
| Melphalan Hydrochloride | 37 | 61.6 | 61.7 |
| Etoposide | 95 | 60.9 | 61.0 |
| Cytarabine | 72 | 53.7 | 53.8 |
| Bendamustine Hydrochloride | 14 | 46.7 | 46.7 |
| Vincristine Sulfate | 31 | 43.6 | 43.7 |
| Cisplatin | 64 | 36.1 | 36.1 |
| Fludarabine Phosphate | 32 | 33.6 | 33.6 |
| Thiotepa | 7 | 28.9 | 28.9 |
| Bleomycin Sulfate | 7 | 26.7 | 26.7 |
| Filgrastim | 23 | 24.8 | 24.8 |
| Mesna Injection | 5 | 23.8 | 23.8 |
| Mesna | 5 | 23.3 | 23.3 |
| Gemcitabine | 21 | 21.5 | 21.6 |
| Polatuzumab Vedotin | 5 | 20.1 | 20.1 |
| Gemcitabine Hydrochloride | 22 | 16.8 | 16.8 |
| Blinatumomab | 3 | 11.2 | 11.2 |